Veris Residential (VRE) Insider Notice — 64,080 Shares via Morgan Stanley
Rhea-AI Filing Summary
Form 144 notice for Veris Residential, Inc. (VRE) reports a proposed sale of 64,080 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,032,924.74 and an approximate sale date of 09/09/2025. The filer discloses that these shares were acquired in three open-market purchases in May 2018 (1,604; 7,488; 54,988 shares) and that no securities were sold by the filer in the past three months per the form. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Positive
- Full disclosure of acquisition details: acquisition dates, quantities, and cash payments are listed
- Use of a major broker: Morgan Stanley Smith Barney LLC is named for execution
- Aggregate market value provided: $1,032,924.74 for transparency
Negative
- None.
Insights
TL;DR: Routine officer/insider sale notice for 64,080 shares valued at ~$1.03M, using a major broker, scheduled for 09/09/2025.
This Form 144 is a procedural disclosure indicating intent to sell shares acquired in 2018. The sale size represents a small fraction of the 93,421,769 shares outstanding shown on the form, and the use of Morgan Stanley Smith Barney LLC is consistent with standard execution channels. There are no reported sales in the prior three months, and the filer affirms no undisclosed material adverse information. For investors, this is a transparency filing rather than a sign of a company-specific event.
TL;DR: Form 144 appears complete for a Rule 144 notice and contains required acquisition and broker details.
The filing provides required acquisition dates, purchase amounts, payment method (cash), broker name, and aggregate market value, which supports regulatory compliance for an intended sale. No anomalies or nonstandard payment arrangements are disclosed. The signature/representation language is present, satisfying the attestation regarding material information. This is a routine regulatory disclosure with limited immediate risk implications for the issuer.